Related references
Note: Only part of the references are listed.Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome
Alexander F. Lipka et al.
NEUROLOGY (2020)
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ
Mirjam E. Hoekstra et al.
NATURE CANCER (2020)
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
Martin McLaughlin et al.
NATURE REVIEWS CANCER (2020)
DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail
Megumi Furuta et al.
CANCER SCIENCE (2019)
Immunotherapy for small cell lung cancer: mechanisms of resistance
Gerhard Hamilton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
The role of T helper 17 and regulatory T cells in tumor microenvironment
Soheil Najafi et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2019)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors
Francesc Graus et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling
Jin-Cheng Zheng et al.
MEDICAL SCIENCE MONITOR (2019)
Abscopal effect of radiation on multiple lung metastases of lung adenocarcinoma: a case report
Aoi Kuroda et al.
BMC CANCER (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
DLL3: an emerging target in small cell lung cancer
Dwight H. Owen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes
Wade T. Iams et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Immunotherapy and radiotherapy for metastatic cancers
Andrew Bang et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
Xiaoliang Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
Grace A. Ward et al.
BLOOD (2019)
Abscopal effect in lung cancer: three case reports and a concise review
Elena Garelli et al.
IMMUNOTHERAPY (2019)
Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma
Lukas W. Pfannenstiel et al.
ONCOIMMUNOLOGY (2019)
Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells
Julia Krombach et al.
ONCOIMMUNOLOGY (2019)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy
A. Sun et al.
CLINICAL ONCOLOGY (2018)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer
Kentaro Tanaka et al.
LUNG CANCER (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Maria E. Rodriguez-Ruiz et al.
TRENDS IN IMMUNOLOGY (2018)
Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis
Ansu Abu Alex et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer
Shirish M. Gadgeel
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
Daniel C. Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
David Paul Carbone et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Will liquid biopsies improve outcomes for patients with small-cell lung cancer?
Fiona Blackhall et al.
LANCET ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
M Reck et al.
ANNALS OF ONCOLOGY (2018)
Development of PARP and Immune-Checkpoint Inhibitor Combinations
Ross A. Stewart et al.
CANCER RESEARCH (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, DoubleBlind Phase 2 Trial
Y. Cheng et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
L.V. Sequist et al.
ANNALS OF ONCOLOGY (2017)
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Fernanda G. Herrera et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Arsenic trioxide is an immune adjuvant in liver cancer treatment
Lei Wang et al.
MOLECULAR IMMUNOLOGY (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity
Qingmin Gao et al.
ONCOLOGY LETTERS (2017)
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Claire Viallard et al.
ANGIOGENESIS (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.
Matthew David Hellmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
Edurne Arriola et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer
Taofeek K. Owonikoko et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Grit S. Herter-Sprie et al.
JCI INSIGHT (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance)
Neal E. Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman et al.
LANCET (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation
A. Kumari et al.
CELL DEATH AND DIFFERENTIATION (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
Antitumor immune responses induced by ionizing irradiation and further immune stimulation
Benjamin Frey et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
Francois Ghiringhelli et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Frueh et al.
ANNALS OF ONCOLOGY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A new strategy to target regulatory T cells in solid tumors
Audrey Thomas-Schoemann et al.
ONCOIMMUNOLOGY (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer
Audrey Thomas-Schoemann et al.
JOURNAL OF IMMUNOLOGY (2012)
Curing APL through PML/RARA degradation by As2O3
Valerie Lallemand-Breitenbach et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
A cell autonomous role for the Notch ligand Delta-like 3 in αβ T-cell development
Gerard F. Hoyne et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Mickael Michaud et al.
SCIENCE (2011)
Treatment options for small cell lung cancer - do we have more choice?
M. Puglisi et al.
BRITISH JOURNAL OF CANCER (2010)
Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity
Laetitia Aymeric et al.
CANCER RESEARCH (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Siow Ming Lee et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Review: Targeted therapies in small cell lung cancer: a review
Aidalena Z. Abidin et al.
Therapeutic Advances in Medical Oncology (2009)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada clinical trials group study BR. 20
Andrew M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Small cell lung cancer: Have we made any progress over the last 25 years?
Brian E. Lally et al.
ONCOLOGIST (2007)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Prophylactic cranial irradiation in extensive small-cell lung cancer
Ben Slotman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20
A. M. Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
S Gasser et al.
NATURE (2005)
PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase
CM Simbulan-Rosenthal et al.
ONCOGENE (2003)
A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma
G Fontanini et al.
BRITISH JOURNAL OF CANCER (2002)
Arsenic trioxide, a therapeutic agent for APL
TD Zhang et al.
ONCOGENE (2001)
Share Paper
